# Eli Lilly, Novo Nordisk and Pfizer Lead Healthcare Headlines Pharmaceutical giants dominated this week's investment agenda. - **Source:** [Breaking News on Seeking Alpha](https://brifing.si/source/9a596115-e1cc-45e7-b5ba-070be9ea2998) - **Published:** 2026-08-09 - **Topic:** [Business](https://brifing.si/c/business) - **Original article:** - **On Brifing:** https://brifing.si/s/6118dc42-18cb-45e3-b400-16a4170691fc ## Weekly Market Performance Wall Street's major indices closed higher on Friday despite disappointing July nonfarm payroll data. The Dow Jones rose 0.3%, S&P 500 gained 0.62%, and Nasdaq Composite jumped 1.3%. This upward movement particularly boosted investor interest in healthcare stocks. ## Eli Lilly's Recent Performance Eli Lilly, a key player in diabetes and obesity drugs, reported better-than-expected quarterly revenue. Sales of Mounjaro, containing tirzepatide, surged 72% year-over-year. Analysts predict continued growth in the obesity drug market, with Lilly well-positioned to capitalize. ## Novo Nordisk's Growth Surge Danish pharmaceutical giant Novo Nordisk saw strong stock performance driven by Wegovy's rising US sales. Q2 revenue grew 32% to $5.9 billion. Investors estimate the obesity treatment market could exceed $100 billion by 2030, with Novo maintaining significant market share. ## Pfizer's Strategic Moves Pfizer, known for COVID-19 vaccines, faces post-pandemic revenue declines. The company is pivoting to oncology, recently acquiring cancer drug maker Seagen for $43 billion. Pfizer revised its 2024 revenue guidance to $67-71 billion range, betting on long-term growth in cancer treatments. ## Obesity Drug Market Expansion Global obesity drug market was valued at $2.4 billion in 2022, projected to reach $100 billion by 2030. Novo Nordisk and Eli Lilly currently control 90% of this market. Experts note these drugs' effectiveness in diabetes treatment further expands their potential market size. ## Healthcare R&D Investments Pharma companies invested $137 billion in R&D during 2022. Pfizer alone spent $11.4 billion while Novo Nordisk allocated $3.5 billion. These investments concentrate on obesity, diabetes and cancer treatments, with increasing focus on personalized medicine approaches. ## Investor Perspective Healthcare stocks are considered defensive investments during economic uncertainty. Rising chronic diseases and aging populations support long-term sector growth. Analysts highlight biotech innovations and personalized medicine as creating new investment opportunities in coming years. ## Future Outlook Global healthcare sector is projected to grow 5.5% in 2023. The US Inflation Reduction Act's impact on drug pricing and European regulatory changes will shape industry dynamics. Experts anticipate mRNA technology and gene therapy advancements will transform treatment paradigms. ## Sources covering this story - https://seekingalpha.com/news/4629554-notable-healthcare-headlines-for-the-week-eli-lilly-novo-nordisk-and-pfizer-in-focus?utm_source=feed_news_all&utm_medium=referral&feed_item_type=news — --- _Summary written by Brifing from the original reporting. Copyright in the original article belongs to its publisher; read the full piece at the link above._